Light chain (AL) amyloidosis is a systemic disorder caused by plasma cell dyscrasia, with cardiac involvement being the primary determinant of prognosis. Survival outcomes vary significantly across disease stages. This heterogeneity underscores a critical need for early diagnosis, precise risk stratification, and response-adapted therapy. In this context, multimodality imaging has emerged as an indispensable non-invasive tool, providing crucial insights for clinical decision-making. This review synthesizes recent advances in the application of key imaging modalities—echocardiography, magnetic resonance imaging, and nuclear medicine imaging—for evaluating AL amyloidosis. We highlight how these techniques have shifted the paradigm from anatomical assessment to quantitative, multiparametric tissue characterization, ultimately guiding personalized patient management.